Protagonist Therapeutics (PTGX) Free Cash Flow (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Free Cash Flow of -$49.1 million for Q1 2026, down 139.3% on a YoY basis from $124.8 million in Q1 2025, and down 27.22% sequentially from -$38.6 million in Q4 2025.
Protagonist Therapeutics (PTGX) Free Cash Flow (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Free Cash Flow data on file, last reported at -$49.1 million in Q1 2026.
- For the quarter ending Q1 2026, Free Cash Flow fell 139.3% year-over-year to -$49.1 million; the trailing twelve-month figure through Mar 2026 stood at -$117.8 million (down 135.13% YoY), and the FY2025 full-year result was $56.1 million, down 69.32% from the prior year.
- Free Cash Flow declined to -$49.1 million in Q1 2026, from -$38.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $268.6 million in Q2 2024 to a low of -$49.1 million in Q1 2026.
- A 5-year average of $636705.9 and a median of -$27.7 million in 2024 frame the typical range for Free Cash Flow.
- Peak annual rise in Free Cash Flow reached 1116.84% in 2024, while the deepest fall reached 274.06% in 2024.
- Tracing PTGX's Free Cash Flow over 5 years: stood at -$31.6 million in 2022, then soared by 153.62% to $16.9 million in 2023, then sank by 274.06% to -$29.5 million in 2024, then slumped by 30.75% to -$38.6 million in 2025, then declined by 27.22% to -$49.1 million in 2026.
- Business Quant data shows PTGX's Free Cash Flow at -$49.1 million in Q1 2026, -$38.6 million in Q4 2025, and -$1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.58 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 158.09 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.29 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 848.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.95 Mn |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -49.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.05 Mn |
| Mar 31, 2026 | -49.05 Mn |
| Dec 31, 2025 | -38.56 Mn |
| Dec 31, 2025 | -38.56 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Sep 30, 2025 | -1.84 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Jun 30, 2025 | -28.34 Mn |
| Mar 31, 2025 | 124.82 Mn |
| Mar 31, 2025 | 124.82 Mn |
| Dec 31, 2024 | -29.49 Mn |
| Dec 31, 2024 | -29.49 Mn |
| Sep 30, 2024 | -28.63 Mn |
| Sep 30, 2024 | -28.63 Mn |
| Jun 30, 2024 | 268.59 Mn |
| Jun 30, 2024 | 268.59 Mn |
| Mar 31, 2024 | -27.67 Mn |
| Mar 31, 2024 | -27.67 Mn |
| Dec 31, 2023 | 16.94 Mn |
| Dec 31, 2023 | 16.94 Mn |